Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Dr. W.S.M.E. Theelen, MD PhD
CONTACT
Eline R Harding, MD
CONTACT
Lead
The Netherlands Cancer Institute
With
Early-stage non-small cell lung cancer (NSCLC) patients with a pathological complete response (pCR) to neoadjuvant chemoimmunotherapy are potentially already cured before the local radical treatment is administered. However, treatment de-escalation in these patients is unfeasible since pCR detection before local radical treatment is unreliable. The investigators propose to evaluate if local radical therapy can be omitted after immunotherapy in selected participants with stage Ia NSCLC with high probability of immunotherapy benefit. Participants receive three cycles of 350 milligrams of cemiplimab intravenously every three weeks followed by a radiological and metabolic response evaluation with respectively CT and \[18F\]FDG-PET. Thereafter participants will enter the follow-up phase where response will be closely monitored with CT scans 3-monthly. Additionally, blood will be collected for ctDNA analysis at baseline, during treatment with cemiplimab and follow-up will be collected. According to standard of care, participants will undergo a \[18F\]FDG-PET scan if progressive disease is suspected. Participants with disease recurrence will be treated off-study at the discretion of the treating physician.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
